TARS:NASDAQ, Tarsus Pharmaceuticals, Inc.

TARS stock overview

Tarsus Pharmaceuticals, Inc. (TARS:NASDAQ) closed at $68.20 on October 23, 2026, down 5.38% on the day. The stock trades 25.5% below its 52-week high of $91.53 and 26.6% above its 52-week low of $53.89. Over the past year, it gained 3.2%. Tarsus Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price: $68.20
Day change: -5.38%
Volume: 535,296
Average volume: 835,746
Market cap: 3B+
52-week range: $53.89 – $91.53
50-day average: $75.05
200-day average: $67.93

Price action over the past year

In 252 trading sessions since October 23, 2025, TARS closed higher on 122 days (48%). Its best day was September 2, 2026 (+11.76%) and its worst was July 10, 2026 (-9.35%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.

Recent signals

Oct 23, 2026: Trading sideways between $68.07 and $74.40 over 14 days (Sideways scanner)
Oct 14, 2026: News catalyst: Investor Update (News Catalysts scanner)
Sep 4, 2026: Spiked to $91.53 on 1M+ shares (Spikes scanner)

TARS news

Oct 15, 2026: Lisata adds biopharma finance veteran Jeffrey Farrow to board
Oct 14, 2026: Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Sep 29, 2026: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
Sep 18, 2026: When To Dump Stocks: These IBD 50 Components Hit Sell Signals
Sep 4, 2026: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Sep 1, 2026: Tarsus to Participate in Upcoming Investor Conferences
Aug 13, 2026: Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
Aug 13, 2026: Tarsus (TARS) Q2 2026 Earnings Call Transcript

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Similar stocks

Find more stocks like TARS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.